SCHEMBL3356294

SCHEMBL3356294

CC(C)N1CC2CN(c3ccc4nc(-c5ccc(F)cc5)c(-c5ccnnc5)n4n3)CC2C1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 12/20 0.52
ENPP2 Q13822 2/20 0.38
CSNK1D P48730 3/20 0.36
RIPK3 Q9Y572 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3356336 0.90 CSNK1E (0.55) CSNK1EENPP2CSNK1DRIPK3
SCHEMBL3113054 0.90 CSNK1E (0.65) CSNK1ECSNK1DRIPK3
SCHEMBL3354235 0.88 CSNK1E (0.53) CSNK1ECSNK1DRIPK3
SCHEMBL3354776 0.86 CSNK1E (0.55) CSNK1EENPP2CSNK1DRIPK3
SCHEMBL3104250 0.85 CSNK1E (0.51) CSNK1EENPP2CSNK1DRIPK3
SCHEMBL3357377 0.84 CSNK1E (0.65) CSNK1EENPP2CSNK1DRIPK3
SCHEMBL3357367 0.84 CSNK1E (0.65) CSNK1EENPP2CSNK1DRIPK3
SCHEMBL3116920 0.83 CSNK1E (0.49) CSNK1EENPP2RIPK3
SCHEMBL3356194 0.82 CSNK1E (0.47) CSNK1EENPP2RIPK3
SCHEMBL3356106 0.81 CSNK1E (0.56) CSNK1ECSNK1DRIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108971-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof SANOFI (FR) 2015-08-18 US claimed
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI (FR) 2013-09-19 US claimed
EP-2178879-B1 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2013-07-03 EP claimed
US-8455491-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same SANOFI (FR) 2013-06-04 US claimed
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-06-17 US claimed
US-9108971-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof SANOFI (FR) 2015-08-18 US disclosed
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI (FR) 2013-09-19 US disclosed
US-8455491-B2 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same SANOFI (FR) 2013-06-04 US disclosed
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245023-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF TLR7, IFNAR1, CBR3 CSNK1E 757/4885ENPP2 1332/4885CSNK1D 732/4885
US-20100152157-A1 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF IFNAR1, TLR7, CBR3 CSNK1E 724/4885ENPP2 1343/4885CSNK1D 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.